AR094781A1 - Anticuerpos anti-her2 (receptor 2 del factor de crecimiento epidérmico humano) altamente galactosilados y sus usos - Google Patents
Anticuerpos anti-her2 (receptor 2 del factor de crecimiento epidérmico humano) altamente galactosilados y sus usosInfo
- Publication number
- AR094781A1 AR094781A1 ARP140100460A ARP140100460A AR094781A1 AR 094781 A1 AR094781 A1 AR 094781A1 AR P140100460 A ARP140100460 A AR P140100460A AR P140100460 A ARP140100460 A AR P140100460A AR 094781 A1 AR094781 A1 AR 094781A1
- Authority
- AR
- Argentina
- Prior art keywords
- her2 antibodies
- highly
- galactosilated
- receiver
- growth factor
- Prior art date
Links
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 title 1
- 229940116978 human epidermal growth factor Drugs 0.000 title 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 210000002919 epithelial cell Anatomy 0.000 abstract 2
- 210000005075 mammary gland Anatomy 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
- 229960000575 trastuzumab Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764488P | 2013-02-13 | 2013-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094781A1 true AR094781A1 (es) | 2015-08-26 |
Family
ID=50980322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100460A AR094781A1 (es) | 2013-02-13 | 2014-02-13 | Anticuerpos anti-her2 (receptor 2 del factor de crecimiento epidérmico humano) altamente galactosilados y sus usos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150368357A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2956485A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2016509019A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160003634A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105308071A (cg-RX-API-DMAC7.html) |
| AR (1) | AR094781A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014217564B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015019343A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2900912A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL240440A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015010428A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201444870A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014125377A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103429272A (zh) | 2010-12-30 | 2013-12-04 | 法国化学与生物科技实验室 | 作为病原体灭活剂的二元醇 |
| KR20160002713A (ko) | 2013-02-13 | 2016-01-08 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도 |
| CN105263319A (zh) | 2013-02-13 | 2016-01-20 | 法国化学与生物科技实验室 | 具有经修饰的糖基化的蛋白及其生产方法 |
| MX384222B (es) | 2013-07-05 | 2025-03-14 | Lab Francais Du Fractionnement | Matriz de cromatografia de afinidad. |
| WO2016037947A1 (en) * | 2014-09-10 | 2016-03-17 | F. Hoffmann-La Roche Ag | Galactoengineered immunoglobulin 1 antibodies |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| CN105669964B (zh) * | 2016-03-04 | 2017-11-21 | 博瑞生物医药（苏州）股份有限公司 | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 |
| FR3060395B1 (fr) | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-her2 |
| MA52783A (fr) * | 2018-06-05 | 2021-04-14 | Amgen Inc | Modulation de la phagocytose cellulaire dépendant de l'anticorps |
| CN112566667B (zh) * | 2018-06-15 | 2023-06-09 | 上海美雅珂生物技术有限责任公司 | 治疗癌症的方法和材料 |
| WO2022022526A1 (zh) * | 2020-07-28 | 2022-02-03 | 百奥泰生物制药股份有限公司 | 抗her2抗体及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US5843705A (en) | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| ES2434961T5 (es) * | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| CA2447851C (en) | 2001-06-28 | 2012-08-28 | Domantis Limited | Dual-specific ligand and its use |
| ES2561985T3 (es) * | 2001-10-10 | 2016-03-01 | Ratiopharm Gmbh | Remodelación y glicoconjugación de anticuerpos |
| US20040101939A1 (en) * | 2002-11-22 | 2004-05-27 | Santora Ling C. | Method for reducing or preventing modification of a polypeptide in solution |
| FR2861080B1 (fr) * | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
| US20060127950A1 (en) | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| US20060057638A1 (en) | 2004-04-15 | 2006-03-16 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| US20060182744A1 (en) * | 2005-02-15 | 2006-08-17 | Strome Scott E | Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| CN101484470B (zh) * | 2005-10-21 | 2014-07-23 | 阿伊沃生物制剂有限公司 | 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途 |
| CA2655246A1 (en) * | 2006-06-09 | 2007-12-21 | University Of Maryland, Baltimore | Glycosylation engineered antibody therapy |
| LT2511301T (lt) * | 2006-08-04 | 2018-04-10 | Medimmune Limited | Žmogaus antikūnas prieš erbb2 |
| ZA200901912B (en) * | 2006-09-10 | 2010-06-30 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| KR101603632B1 (ko) * | 2006-09-10 | 2016-03-16 | 글리코토페 게엠베하 | 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도 |
| CA2734139C (en) * | 2007-10-02 | 2019-12-24 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
| US8084222B2 (en) * | 2008-09-26 | 2011-12-27 | Eureka Therapeutics, Inc. | Methods for generating host cells |
| JPWO2012105699A1 (ja) * | 2011-02-03 | 2014-07-03 | 株式会社イーベック | 補体依存性生物活性の高い抗体の産生法 |
| US8809017B2 (en) * | 2011-05-24 | 2014-08-19 | Agency For Science, Technology And Research | IRES mediated multicistronic vectors |
| KR20160002713A (ko) * | 2013-02-13 | 2016-01-08 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도 |
-
2014
- 2014-02-13 AU AU2014217564A patent/AU2014217564B2/en not_active Ceased
- 2014-02-13 EP EP14732000.6A patent/EP2956485A2/en not_active Withdrawn
- 2014-02-13 US US14/767,120 patent/US20150368357A1/en not_active Abandoned
- 2014-02-13 BR BR112015019343A patent/BR112015019343A2/pt not_active Application Discontinuation
- 2014-02-13 KR KR1020157024975A patent/KR20160003634A/ko not_active Withdrawn
- 2014-02-13 MX MX2015010428A patent/MX2015010428A/es unknown
- 2014-02-13 TW TW103104772A patent/TW201444870A/zh unknown
- 2014-02-13 CA CA2900912A patent/CA2900912A1/en not_active Abandoned
- 2014-02-13 WO PCT/IB2014/000711 patent/WO2014125377A2/en not_active Ceased
- 2014-02-13 CN CN201480020373.3A patent/CN105308071A/zh active Pending
- 2014-02-13 JP JP2015557533A patent/JP2016509019A/ja active Pending
- 2014-02-13 AR ARP140100460A patent/AR094781A1/es unknown
-
2015
- 2015-08-09 IL IL240440A patent/IL240440A0/en unknown
-
2019
- 2019-12-27 JP JP2019238917A patent/JP2020125286A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201444870A (zh) | 2014-12-01 |
| MX2015010428A (es) | 2016-04-13 |
| WO2014125377A2 (en) | 2014-08-21 |
| CN105308071A (zh) | 2016-02-03 |
| WO2014125377A3 (en) | 2014-12-04 |
| KR20160003634A (ko) | 2016-01-11 |
| AU2014217564B2 (en) | 2018-11-08 |
| JP2020125286A (ja) | 2020-08-20 |
| IL240440A0 (en) | 2015-09-24 |
| JP2016509019A (ja) | 2016-03-24 |
| US20150368357A1 (en) | 2015-12-24 |
| EP2956485A2 (en) | 2015-12-23 |
| CA2900912A1 (en) | 2014-08-21 |
| BR112015019343A2 (pt) | 2017-08-22 |
| AU2014217564A1 (en) | 2015-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094781A1 (es) | Anticuerpos anti-her2 (receptor 2 del factor de crecimiento epidérmico humano) altamente galactosilados y sus usos | |
| BR112015019341A2 (pt) | Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal | |
| MX2011013781A (es) | Anticuerpos anti-vegf y sus usos. | |
| MX2013014937A (es) | Cultivo de celulas de mamifero. | |
| AR094779A1 (es) | Cetuximab con glicosilación modificada y sus usos | |
| MX2018000344A (es) | Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano. | |
| EA202092202A1 (ru) | Конструкции антител к ror | |
| NI201300023A (es) | Anticuerpos para el receptor 3 del factor de crecimiento epidérmico (her 3) | |
| EA201490343A1 (ru) | Светоизлучающее стекло транспортного средства и его производство | |
| BR112012025739A2 (pt) | corpo de guia de luz, método para produzir um corpo de guia de luz e uso de um corpo de guia de luz | |
| CO7111273A2 (es) | Anticuerpos cd47 y métodos de uso de los mismos | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| CL2011002039A1 (es) | Anticuerpo humanizado que se une al cd19 humano; acido nucleico aislado que codifica dicho anticuerpo; vector y celula huesped; composicion e inmunoconjugado; metodo para inhibir el crecimiento de celulas de tumor que expresan cd19. | |
| AR065420A1 (es) | Anticuerpos anti-il-23 p19 de ingenieria | |
| EP4477668A3 (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
| PE20121063A1 (es) | Anticuerpos anti-cdcp1 humanizados | |
| MX2019003427A (es) | Composiciones para cultivo celular y metodos para la produccion de polipeptidos. | |
| CY1119602T1 (el) | Συνθεσεις και μεθοδοι για παραγωγη γλυκοπρωτεϊνων | |
| IN2014DN09244A (cg-RX-API-DMAC7.html) | ||
| AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos | |
| CL2012002700A1 (es) | Anticuerpo humanizado capaz de logarse especificamente a receptores de quimioquina 4 (cxcr4); molecula de acido nucleico aislada que codifica dicho anticuerpo; vector y célula que comprenden dicho acido nucleico; composicion que comprende dicho anticuerpo; proceso de deteccion in vitro de la presencia y/o la ubicacion de un tumor que expresa cxcr4. | |
| BR112021024852A2 (pt) | Métodos de cultura de célula e composições para produção de anticorpo | |
| AR072206A1 (es) | Sistema en continuo de transformacion de co2 en productos de alto valor anadido y/o valor nutricional y otros recursos energeticos | |
| AR085824A1 (es) | Anticuerpo anti-receptor il-3 humano | |
| EA201690271A1 (ru) | Конструкции для экспрессии и способы экспрессии полипептидов в клетках эукариот |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |